COVID-19 Vaccines and Treatment: The Race for Global Equity

We have stopped tracking COVID-19 bivalent vaccine purchases, vaccine donations, and therapeutics data as of May 5, 2023. The latest data update available on the website includes bivalent vaccine purchases, vaccine donations, and therapeutics data. Data on the COVID-19 vaccine purchases and manufacturing data was last updated July 1, 2022 and is also available on the website. The latest date can be downloaded here:

As always, please let us know if you have any questions or spot any gaps or discrepancies in the data, and if you have found the data useful we would love to hear how you have used it.

For further questions or other media requests, please email Melissa Estrada,

Our team aggregates and analyzes publicly available data to track the purchases, manufacturing, and donations of COVID-19 vaccines and therapeutics. The data are provided in interactive visuals on this site, as well as in a downloadable spreadsheet (updated regularly), to strengthen data-driven understandings of the global equity challenges and potential solutions in pandemic response. Please contact us at with any additions or corrections to the data presented here.

COVID Vaccine Purchases

COVID Vaccine Manufacturing

COVID Vaccine Donations

COVID Therapeutics

Latest COVID-19 Vaccine and Therapeutics Data

Download our latest vaccine donations data update from May 5, 2023 (.xlsx).

Download our latest therapeutics data update from May 5, 2023 (.xlsx).

Archived vaccine data (downloads available).

Featured Publications

Read the Framework for a Global Action Plan for COVID-19 Response released Tuesday, August 24, 2021

We are at an exceedingly perilous and urgent moment in the COVID-19 pandemic. As the Delta variant has demonstrated, we are fighting a virus that doesn’t respect borders and rapidly advances across continents. If the virus continues to circulate unchecked in large parts of the world, we will see not only many more millions of infections and deaths, but also new variants that could totally pierce vaccine immunity, returning the world to square one.  

Read our August 2, 2021 Open Letter to the Biden-Harris Administration: US Emergency Plan for Global COVD-19 Relief

We are at an exceedingly perilous and urgent moment in the COVID-19 pandemic. The Delta variant, vastly more dangerous and pernicious than the original SARS-CoV-2 virus, has rapidly spread worldwide. It has been driving a deadly summer surge in the US; ripping through Latin America; causing Indonesia to become the next Asian hotspot; and fueling a third wave of the pandemic in Africa, where less than two percent of the population has been fully vaccinated. To respond, the US must build on the rapid development and availability of its highly effective vaccines – ensuring easy access for any American who wants to be vaccinated, and readiness to rapidly deploy boosters and vaccines for children. But as Delta has shown, an effective domestic response is not enough. Read more here.

Read The Hill's July 8, 2021article: Beyond ample supply, hurdles abound in the race to vaccinate the globe

Read our June 7, 2021 Open Letter to the G7: U.S. Global Health Experts Urge G7 Action to Vaccinate the World Quickly and Equitably

Read our May 17, 2021 Open Letter to the Biden Administration and US Congress Calling for Urgent High-Level US Leadership to Address Escalating Global COVID-19 Vaccine Crisis

Read our May 1, 2021 Op-Ed in the MIT Technology Review: What India needs to get through its covid crisis 

Read our April 28, 2021 Op-Ed from The Hill: Poorer nations face tougher choice about vaccines

Read our April 28, 2021 Op-Ed from Politico: Why America’s Next Covid Push Should Be Outside America

Read our April 15, 2021 paper on Reducing Global COVID Vaccine Shortages: New Research and Recommendations for US Leadership

Read our March 19, 2021 Issue Brief: Deciphering the Manufacturing Landscape for COVID-19 Vaccines.

Read our November 2, 2020 Press Release on COVID-10 Vaccine Advance Market Commitments.

Our research has recently been featured in The New York Times, The Washington Post, The Economist, Bloomberg, and The Guardian and many other outlets, including El Diario in Spain, as well as Al Jazeera. View and listen to these brief commentaries from our research team on BBCNPR, NYPoficial (Paraguay) and ABC News.

Featuring Dr. Krishna Udayakumar, Director, Duke GHIC - VOX, April 28, 2021

Dr. Ernesto Ortiz

Dr. Ernesto Ortiz, Senior Manager - CNN Espanol, February 22, 2021

For Media Requests please email Jessica Harris at or call + 1 919 668 7923.  

These data and analyses are updated every week. We are tracking the data to the best of our ability, though there may be gaps given the speed of developments and lack of detailed information in many public statements.

Suggested citation: Duke Global Health Innovation Center. (2021). Launch and Scale Speedometer. Duke University. Retrieved from:

Except where otherwise noted, this work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.